FeesSafety
Pluang+

Bitcoin price dips 0.10% with trading volume down 35%, signaling cautious market activity.

Market News
23 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin price dips 0.10% with trading volume down 35%, signaling cautious market activity.

Bitcoin's price slightly fell by 0.10% to $81,617 amid a sharp 34.92% drop in trading volume, indicating weaker market participation and subdued buying activity. Sentiment cooled to neutral, with the Fear and Greed Index dropping to 50, while net inflows to exchanges added 34,363 BTC, increasing potential selling supply. Despite the price decline, search interest rose, showing mixed signals between public attention and trading activity. The overall picture suggests cautious investor sentiment and a market waiting for clearer direction.

Bitcoin price movement is presented here with Pluang's market data as context. As of Oct 23, 2026 19:01 WIB, 26 of 50 major cryptocurrencies on Pluang rose while 23 fell. Notable movers include BCH at Rp5.132.608 with a 1-day change of +2.72% and a typical hold time of 69 days, and CRV at Rp6.541 with a 1-day change of -2.65%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
23 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
23 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
23 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App